0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Cardiovascular medicine

Buy Now

Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia - Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 (Paperback, Softcover reprint of the original 1st ed. 1990) Loot Price: R4,469
Discovery Miles 44 690
Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart...

Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia - Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 (Paperback, Softcover reprint of the original 1st ed. 1990)

J. Morganroth, E.Neil Moore

Series: Developments in Cardiovascular Medicine, 112

 (sign in to rate)
Loot Price R4,469 Discovery Miles 44 690 | Repayment Terms: R419 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect.

General

Imprint: Springer-Verlag New York
Country of origin: United States
Series: Developments in Cardiovascular Medicine, 112
Release date: October 2011
First published: 1990
Editors: J. Morganroth • E.Neil Moore
Dimensions: 235 x 155 x 13mm (L x W x T)
Format: Paperback
Pages: 230
Edition: Softcover reprint of the original 1st ed. 1990
ISBN-13: 978-1-4612-8809-1
Categories: Books > Medicine > Clinical & internal medicine > Cardiovascular medicine
LSN: 1-4612-8809-6
Barcode: 9781461288091

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners